Document Detail

Estimating the likelihood of sustained virological response in chronic hepatitis C therapy.
MedLine Citation:
PMID:  20849436     Owner:  NLM     Status:  In-Process    
The likelihood of a sustained virological response (SVR) is the most important factor for physicians and patients in the decision to initiate and continue therapy for chronic hepatitis C (CHC) infection. This study identified predictive factors for SVR with peginterferon plus ribavirin (RBV) in patients with CHC treated under 'real-life' conditions. The study cohort consisted of patients from a large, retrospective German multicentre, observational study who had been treated with peginterferon alfa-2a plus RBV or peginterferon alfa-2b plus RBV between the years 2000 and 2007. To ensure comparability regarding peginterferon therapies, patients were analysed in pairs matched by several baseline variables. Univariate and multivariate logistic regression analyses were used to determine the effect of nonmatched baseline variables and treatment modality on SVR. Among 2378 patients (1189 matched pairs), SVR rates were 57.9% overall, 46.5% in HCV genotype 1/4-infected patients and 77.3% in genotype 2/3-infected patients. In multivariate logistic regression analysis, positive predictors of SVR were HCV genotype 2 infection, HCV genotype 3 infection, low baseline viral load and treatment with peginterferon alfa-2a. Negative predictors of SVR were higher age (≥40 years), elevated baseline gamma-glutamyl transpeptidase (GGT) and low baseline platelet count (<150,000/μL). Among patients treated with peginterferon plus RBV in routine clinical practice, genotype, baseline viral load, age, GGT level and platelet levels all predict the likelihood of treatment success. In patients matched by baseline characteristics, treatment with peginterferon alfa-2a may be a positive predictor of SVR when compared to peginterferon alfa-2b.
S Mauss; D Hueppe; C John; J Goelz; R Heyne; B Moeller; R Link; G Teuber; A Herrmann; M Spelter; S Wollschlaeger; A Baumgarten; K-G Simon; N Dikopoulos; T Witthoeft
Related Documents :
17450036 - Hepatic steatosis has no impact on the outcome of treatment in patients with chronic he...
16164396 - Patient education and treatment strategies implemented at a pharmacist-managed hepatiti...
20400406 - Degree of viral decline early in treatment predicts sustained virological response in h...
18839776 - Dynamic evolution of therapy for chronic hepatitis c: how will novel agents be incorpor...
21554996 - High baseline interleukine-8 level is an independent risk factor for the achievement of...
7688596 - Cytokine modulation of hiv expression.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-16
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  18     ISSN:  1365-2893     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  England    
Other Details:
Languages:  eng     Pagination:  e81-90     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Center for HIV and Hepatogastroenterology, Düsseldorf, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combined modality of mechanical breakdown and intraembolus thrombolysis in failed systemic thromboly...
Next Document:  Psychological stress is associated with relapse in type 1 autoimmune hepatitis.